Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Behav Brain Res. 2015 Jun 18;292:194–208. doi: 10.1016/j.bbr.2015.06.015

Figure 9. Effect of dopamine antagonists on COS consumption.

Figure 9

The effect of the D1 antagonist SCH23390 (A,B) and the D2 antagonist raclopride (C,D) injection in the core (A,C) and the shell (B,D) on COS consumption during the first quarter of the session (left) and the last 3 quarters of the session (right) for the IA (black), WA (white) and CA (grey) groups.

*, **, ***: significant difference from the WA group (p < 0.05, 0.01, 0.001).

$, $$, $$$: significant difference from the CA group (p < 0.05, 0.01, 0.001).